Search

Your search keyword '"Juncos, Jorge L"' showing total 192 results
Start Over Author "Juncos, Jorge L"
192 results on '"Juncos, Jorge L"'

1. Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial

Author

Afshari, Mitra, Amelin, Alexander, Arkadir, David, Badarny, Samih, Balaguer Martinez, Ernest, Bogucki, Andrzej, Boyd, James, Buyan Dent, Laura, Carroll, Camille, Chaudhuri, Kallol Ray, Cooney, Jeffrey, Corbillé, Anne-Gaëlle, Danaila, Teodor, De Pandis, Maria Francesca, Dethy, Sophie, Dhall, Rohit, Djaldetti, Ruth, Durif, Franck, Flitman, Stephen, Freire Alvarez, Eric, Goudreau, John, Grandas Perez, Francisco, Gurevich, Tanya, Isa, Arnaldo, Juncos, Jorge L, Kanchana, Sulada, Klodowska-Duda, Gabriela, Koziorowski, Dariusz, Kulisevsky Bojarski, Jaime, Lopez Lozano, Juan, Luo, Lan, Lytvynenko, Nataliya, Marconi, Roberto, Marques, Ana-Raquel, Martinez Castrillo, Juan Carlos, Martinez Torres, Irene, Mentreddi, Aashoo, Mir Rivera, Pablo, Moskovko, Sergii, Neryanova, Yuliya, Onofrj, Marco, Ostrem, Jill, Pacchetti, Claudio, Pavese, Nicola, Pellicano, Clelia, Revuelta, Gonzalo, Rodrigues, Ana Margarida, Rodriguez, Ramon, Rudzinska, Monika, Sarwar, Nighat, Schwartzbard, Julie, Scorr, Laura, Slevin, John, Slobodin, Tatyana, Spalletta, Gianfranco, Tagliati, Michele, Tai, Yen, Tessitore, Alessandro, Valkovic, Peter, Verhagen, Leo, Vostrikova, Elena, Yahalom, Gilad, Zalyalova, Zuleykha, Zarubova, Katerina, Zhukova, Irina, Espay, Alberto J, Stocchi, Fabrizio, Pahwa, Rajesh, Albanese, Alberto, Ellenbogen, Aaron, Ferreira, Joaquim J, Giladi, Nir, Hassin-Baer, Sharon, Hernandez-Vara, Jorge, Isaacson, Stuart H, Kieburtz, Karl, LeWitt, Peter A, Lopez-Manzanares, Lydia, Olanow, C Warren, Poewe, Werner, Sarva, Harini, Yardeni, Tami, Adar, Liat, Salin, Laurence, Lopes, Nelson, Sasson, Nissim, Case, Ryan, and Rascol, Olivier

Published
2024
Full Text
View/download PDF

2. Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?

Author

Shoeibi, Ali, Litvan, Irene, Juncos, Jorge L, Bordelon, Yvette, Riley, David, Standaert, David, Reich, Stephen G, Shprecher, David, Hall, Deborah, Marras, Connie, Kluger, Benzi, Olfati, Nahid, and Jankovic, Joseph

Subjects
Genetics, Clinical Research, Neurodegenerative, Neurosciences, Parkinson's Disease, Rare Diseases, Brain Disorders, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Neurological, Humans, Phenotype, Societies, Medical, Supranuclear Palsy, Progressive, Progressive supranuclear palsy, Criteria, Diagnosis, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

The International Parkinson Disease and Movement Disorder Society PSP study group (IPMDS-PSP) recently published new clinical diagnostic criteria for progressive supranuclear palsy (PSP). Currently, there is no data regarding the accuracy of these sets of criteria for differentiating various PSP phenotypes. We discuss the accuracy of the IPMDS-PSP criteria for differentiation of patients with the PSP- Richardson phenotype (PSP-RS) from those with the PSP-Parkinsonism (PSP-P) using data from a sample of 274 clinically diagnosed PSP patients participating in the Environmental Genetic PSP (ENGENE-PSP) case control study. Using National Institute of Neurological Disorders and Stroke and the Society for PSP (NINDS-SPSP) criteria and the Williams criteria we categorized 259 of these patients as probable PSP-RS and 15 as PSP-P. The IPD-MDS PSP-RS and PSP-P criteria were unable to distinguish the PSP-RS from the PSP-P phenotypes in this sample. Nearly all (92.6%; 240 out of 259) the PSP-RS patients and over half (60%; 9 out of 15) of the PSP-P patients fulfilled both the IPMDS criteria for PSP-RS and PSP-P. Applying the newly proposed multiple allocation extinction rules decreased the number of overlapping diagnoses among the NINDS-SPSP PSP-RS patients, however problems remained in the PSP-P group. Diagnostic accuracy might be improved by modification of timelines for development of falls and other parkinsonian features.

Published
2019

3. Frequency of the TREM2 R47H Variant in Various Neurodegenerative Disorders

Author

Ayer, Ariane H, Wojta, Kevin, Ramos, Eliana Marisa, Dokuru, Deepika, Chen, Jason A, Karydas, Anna M, Papatriantafyllou, John D, Agiomyrgiannakis, Dimitrios, Kamtsadeli, Vasiliki, Tsinia, Niki, Sali, Dimitra, Gylys, Karen H, Agosta, Federica, Filippi, Massimo, Small, Gary W, Bennett, David A, Gearing, Marla, Juncos, Jorge L, Kramer, Joel, Lee, Suzee E, Yokoyama, Jennifer S, Mendez, Mario F, Chui, Helena, Zarow, Chris, Ringman, John M, Kilic, Ulkan, Babacan-Yildiz, Gülsen, Levey, Allan, DeCarli, Charles S, Cotman, Carl W, Boxer, Adam L, Miller, Bruce L, and Coppola, Giovanni

Subjects
Biomedical and Clinical Sciences, Biological Psychology, Clinical Sciences, Neurosciences, Psychology, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Alzheimer's Disease Related Dementias (ADRD), Neurodegenerative, Brain Disorders, Alzheimer's Disease, Acquired Cognitive Impairment, Dementia, Rare Diseases, Frontotemporal Dementia (FTD), Aging, Aetiology, 2.1 Biological and endogenous factors, Neurological, Aged, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Cognitive Dysfunction, Cohort Studies, Female, Frontotemporal Dementia, Genetic Predisposition to Disease, Genetic Variation, Genotype, Humans, Internationality, Male, Membrane Glycoproteins, Neurodegenerative Diseases, Receptors, Immunologic, Alzheimer disease, frontotemporal dementia, genetics, TREM2, progressive supranuclear palsy, mild cognitive impairment, corticobasal syndrome, amyotrophic lateral sclerosis, association study, Cognitive Sciences, Geriatrics, Clinical sciences, Biological psychology
Abstract

ObjectiveA rare variant in TREM2 (p.R47H, rs75932628) has been consistently reported to increase the risk for Alzheimer disease (AD), while mixed evidence has been reported for association of the variant with other neurodegenerative diseases. Here, we investigated the frequency of the R47H variant in a diverse and well-characterized multicenter neurodegenerative disease cohort.MethodsWe examined the frequency of the R47H variant in a diverse neurodegenerative disease cohort, including a total of 3058 patients clinically diagnosed with AD, frontotemporal dementia spectrum syndromes, mild cognitive impairment, progressive supranuclear palsy syndrome, corticobasal syndrome, or amyotrophic lateral sclerosis and 5089 control subjects.ResultsWe observed a significant association between the R47H variant and AD, while no association was observed with any other neurodegenerative disease included in this study.ConclusionsOur results support the consensus that the R47H variant is significantly associated with AD. However, we did not find evidence for association of the R47H variant with other neurodegenerative diseases.

Published
2019

4. Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial

Author

Espay, Alberto J, primary, Stocchi, Fabrizio, additional, Pahwa, Rajesh, additional, Albanese, Alberto, additional, Ellenbogen, Aaron, additional, Ferreira, Joaquim J, additional, Giladi, Nir, additional, Gurevich, Tanya, additional, Hassin-Baer, Sharon, additional, Hernandez-Vara, Jorge, additional, Isaacson, Stuart H, additional, Kieburtz, Karl, additional, LeWitt, Peter A, additional, Lopez-Manzanares, Lydia, additional, Olanow, C Warren, additional, Poewe, Werner, additional, Sarva, Harini, additional, Yardeni, Tami, additional, Adar, Liat, additional, Salin, Laurence, additional, Lopes, Nelson, additional, Sasson, Nissim, additional, Case, Ryan, additional, Rascol, Olivier, additional, Afshari, Mitra, additional, Amelin, Alexander, additional, Arkadir, David, additional, Badarny, Samih, additional, Balaguer Martinez, Ernest, additional, Bogucki, Andrzej, additional, Boyd, James, additional, Buyan Dent, Laura, additional, Carroll, Camille, additional, Chaudhuri, Kallol Ray, additional, Cooney, Jeffrey, additional, Corbillé, Anne-Gaëlle, additional, Danaila, Teodor, additional, De Pandis, Maria Francesca, additional, Dethy, Sophie, additional, Dhall, Rohit, additional, Djaldetti, Ruth, additional, Durif, Franck, additional, Flitman, Stephen, additional, Freire Alvarez, Eric, additional, Goudreau, John, additional, Grandas Perez, Francisco, additional, Isa, Arnaldo, additional, Juncos, Jorge L, additional, Kanchana, Sulada, additional, Klodowska-Duda, Gabriela, additional, Koziorowski, Dariusz, additional, Kulisevsky Bojarski, Jaime, additional, Lopez Lozano, Juan, additional, Luo, Lan, additional, Lytvynenko, Nataliya, additional, Marconi, Roberto, additional, Marques, Ana-Raquel, additional, Martinez Castrillo, Juan Carlos, additional, Martinez Torres, Irene, additional, Mentreddi, Aashoo, additional, Mir Rivera, Pablo, additional, Moskovko, Sergii, additional, Neryanova, Yuliya, additional, Onofrj, Marco, additional, Ostrem, Jill, additional, Pacchetti, Claudio, additional, Pavese, Nicola, additional, Pellicano, Clelia, additional, Revuelta, Gonzalo, additional, Rodrigues, Ana Margarida, additional, Rodriguez, Ramon, additional, Rudzinska, Monika, additional, Sarwar, Nighat, additional, Schwartzbard, Julie, additional, Scorr, Laura, additional, Slevin, John, additional, Slobodin, Tatyana, additional, Spalletta, Gianfranco, additional, Tagliati, Michele, additional, Tai, Yen, additional, Tessitore, Alessandro, additional, Valkovic, Peter, additional, Verhagen, Leo, additional, Vostrikova, Elena, additional, Yahalom, Gilad, additional, Zalyalova, Zuleykha, additional, Zarubova, Katerina, additional, and Zhukova, Irina, additional

Published
2024
Full Text
View/download PDF

6. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.

Author

Kouri, Naomi, Ross, Owen A, Dombroski, Beth, Younkin, Curtis S, Serie, Daniel J, Soto-Ortolaza, Alexandra, Baker, Matthew, Finch, Ni Cole A, Yoon, Hyejin, Kim, Jungsu, Fujioka, Shinsuke, McLean, Catriona A, Ghetti, Bernardino, Spina, Salvatore, Cantwell, Laura B, Farlow, Martin R, Grafman, Jordan, Huey, Edward D, Ryung Han, Mi, Beecher, Sherry, Geller, Evan T, Kretzschmar, Hans A, Roeber, Sigrun, Gearing, Marla, Juncos, Jorge L, Vonsattel, Jean Paul G, Van Deerlin, Vivianna M, Grossman, Murray, Hurtig, Howard I, Gross, Rachel G, Arnold, Steven E, Trojanowski, John Q, Lee, Virginia M, Wenning, Gregor K, White, Charles L, Höglinger, Günter U, Müller, Ulrich, Devlin, Bernie, Golbe, Lawrence I, Crook, Julia, Parisi, Joseph E, Boeve, Bradley F, Josephs, Keith A, Wszolek, Zbigniew K, Uitti, Ryan J, Graff-Radford, Neill R, Litvan, Irene, Younkin, Steven G, Wang, Li-San, Ertekin-Taner, Nilüfer, Rademakers, Rosa, Hakonarsen, Hakon, Schellenberg, Gerard D, and Dickson, Dennis W

Subjects
Cerebral Cortex, Humans, Basal Ganglia Diseases, Supranuclear Palsy, Progressive, Neurodegenerative Diseases, Kinesin, SOS1 Protein, tau Proteins, Myelin Proteins, Case-Control Studies, Polymorphism, Single Nucleotide, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Genome-Wide Association Study, Young Adult, RNA, Long Noncoding, and over, Polymorphism, Single Nucleotide, RNA, Long Noncoding, Supranuclear Palsy, Progressive
Abstract

Corticobasal degeneration (CBD) is a neurodegenerative disorder affecting movement and cognition, definitively diagnosed only at autopsy. Here, we conduct a genome-wide association study (GWAS) in CBD cases (n=152) and 3,311 controls, and 67 CBD cases and 439 controls in a replication stage. Associations with meta-analysis were 17q21 at MAPT (P=1.42 × 10(-12)), 8p12 at lnc-KIF13B-1, a long non-coding RNA (rs643472; P=3.41 × 10(-8)), and 2p22 at SOS1 (rs963731; P=1.76 × 10(-7)). Testing for association of CBD with top progressive supranuclear palsy (PSP) GWAS single-nucleotide polymorphisms (SNPs) identified associations at MOBP (3p22; rs1768208; P=2.07 × 10(-7)) and MAPT H1c (17q21; rs242557; P=7.91 × 10(-6)). We previously reported SNP/transcript level associations with rs8070723/MAPT, rs242557/MAPT, and rs1768208/MOBP and herein identified association with rs963731/SOS1. We identify new CBD susceptibility loci and show that CBD and PSP share a genetic risk factor other than MAPT at 3p22 MOBP (myelin-associated oligodendrocyte basic protein).

Published
2015

7. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit

Author

Beal, M Flint, Oakes, David, Shoulson, Ira, Henchcliffe, Claire, Galpern, Wendy R, Haas, Richard, Juncos, Jorge L, Nutt, John G, Voss, Tiffini Smith, Ravina, Bernard, Shults, Clifford M, Helles, Karen, Snively, Victoria, Lew, Mark F, Griebner, Brian, Watts, Arthur, Gao, Shan, Pourcher, Emmanuelle, Bond, Louisette, Kompoliti, Katie, Agarwal, Pinky, Sia, Cherissa, Jog, Mandar, Cole, Linda, Sultana, Munira, Kurlan, Roger, Richard, Irene, Deeley, Cheryl, Waters, Cheryl H, Figueroa, Angel, Arkun, Ani, Brodsky, Matthew, Ondo, William G, Hunter, Christine B, Jimenez-Shahed, Joohi, Palao, Alicia, Miyasaki, Janis M, So, Julie, Tetrud, James, Reys, Liza, Smith, Katharine, Singer, Carlos, Blenke, Anita, Russell, David S, Cotto, Candace, Friedman, Joseph H, Lannon, Margaret, Zhang, Lin, Drasby, Edward, Kumar, Rajeev, Subramanian, Thyagarajan, Ford, Donna Stuppy, Grimes, David A, Cote, Diane, Conway, Jennifer, Siderowf, Andrew D, Evatt, Marian Leslie, Sommerfeld, Barbara, Lieberman, Abraham N, Okun, Michael S, Rodriguez, Ramon L, Merritt, Stacy, Swartz, Camille Louise, Martin, WR Wayne, King, Pamela, Stover, Natividad, Guthrie, Stephanie, Watts, Ray L, Ahmed, Anwar, Fernandez, Hubert H, Winters, Adrienna, Mari, Zoltan, Dawson, Ted M, Dunlop, Becky, Feigin, Andrew S, Shannon, Barbara, Nirenberg, Melissa Jill, Ogg, Mattson, Ellias, Samuel A, Thomas, Cathi-Ann, Frei, Karen, Bodis-Wollner, Ivan, Glazman, Sofya, Mayer, Thomas, Hauser, Robert A, Pahwa, Rajesh, Langhammer, April, Ranawaya, Ranjit, Derwent, Lorelei, Sethi, Kapil D, Farrow, Buff, Prakash, Rajan, Litvan, Irene, Robinson, Annette, Sahay, Alok, Gartner, Maureen, Hinson, Vanessa K, Markind, Samuel, Pelikan, Melisa, and Perlmutter, Joel S

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Parkinson's Disease, Prevention, Brain Disorders, Complementary and Integrative Health, Clinical Trials and Supportive Activities, Neurodegenerative, Clinical Research, Aging, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Neurological, Aged, Antioxidants, Dose-Response Relationship, Drug, Double-Blind Method, Early Diagnosis, Female, Humans, Male, Middle Aged, Parkinson Disease, Prospective Studies, Treatment Outcome, Ubiquinone, Parkinson Study Group QE3 Investigators, Cognitive Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

ImportanceCoenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function, has been shown in preclinical Parkinson disease (PD) models to reduce the loss of dopamine neurons, and was safe and well tolerated in early-phase human studies. A previous phase II study suggested possible clinical benefit.ObjectiveTo examine whether CoQ10 could slow disease progression in early PD.Design, setting, and participantsA phase III randomized, placebo-controlled, double-blind clinical trial at 67 North American sites consisting of participants 30 years of age or older who received a diagnosis of PD within 5 years and who had the following inclusion criteria: the presence of a rest tremor, bradykinesia, and rigidity; a modified Hoehn and Yahr stage of 2.5 or less; and no anticipated need for dopaminergic therapy within 3 months. Exclusion criteria included the use of any PD medication within 60 days, the use of any symptomatic PD medication for more than 90 days, atypical or drug-induced parkinsonism, a Unified Parkinson's Disease Rating Scale (UPDRS) rest tremor score of 3 or greater for any limb, a Mini-Mental State Examination score of 25 or less, a history of stroke, the use of certain supplements, and substantial recent exposure to CoQ10. Of 696 participants screened, 78 were found to be ineligible, and 18 declined participation.InterventionsThe remaining 600 participants were randomly assigned to receive placebo, 1200 mg/d of CoQ10, or 2400 mg/d of CoQ10; all participants received 1200 IU/d of vitamin E.Main outcomes and measuresParticipants were observed for 16 months or until a disability requiring dopaminergic treatment. The prospectively defined primary outcome measure was the change in total UPDRS score (Parts I-III) from baseline to final visit. The study was powered to detect a 3-point difference between an active treatment and placebo.ResultsThe baseline characteristics of the participants were well balanced, the mean age was 62.5 years, 66% of participants were male, and the mean baseline total UPDRS score was 22.7. A total of 267 participants required treatment (94 received placebo, 87 received 1200 mg/d of CoQ10, and 86 received 2400 mg/d of CoQ10), and 65 participants (29 who received placebo, 19 who received 1200 mg/d of CoQ10, and 17 who received 2400 mg/d of CoQ10) withdrew prematurely. Treatments were well tolerated with no safety concerns. The study was terminated after a prespecified futility criterion was reached. At study termination, both active treatment groups showed slight adverse trends relative to placebo. Adjusted mean changes (worsening) in total UPDRS scores from baseline to final visit were 6.9 points (placebo), 7.5 points (1200 mg/d of CoQ10; P = .49 relative to placebo), and 8.0 points (2400 mg/d of CoQ10; P = .21 relative to placebo).Conclusions and relevanceCoenzyme Q10 was safe and well tolerated in this population, but showed no evidence of clinical benefit.Trial registrationclinicaltrials.gov Identifier: NCT00740714.

Published
2014

8. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Author

Parkinson Study Group QE3 Investigators, Beal, M Flint, Oakes, David, Shoulson, Ira, Henchcliffe, Claire, Galpern, Wendy R, Haas, Richard, Juncos, Jorge L, Nutt, John G, Voss, Tiffini Smith, Ravina, Bernard, Shults, Clifford M, Helles, Karen, Snively, Victoria, Lew, Mark F, Griebner, Brian, Watts, Arthur, Gao, Shan, Pourcher, Emmanuelle, Bond, Louisette, Kompoliti, Katie, Agarwal, Pinky, Sia, Cherissa, Jog, Mandar, Cole, Linda, Sultana, Munira, Kurlan, Roger, Richard, Irene, Deeley, Cheryl, Waters, Cheryl H, Figueroa, Angel, Arkun, Ani, Brodsky, Matthew, Ondo, William G, Hunter, Christine B, Jimenez-Shahed, Joohi, Palao, Alicia, Miyasaki, Janis M, So, Julie, Tetrud, James, Reys, Liza, Smith, Katharine, Singer, Carlos, Blenke, Anita, Russell, David S, Cotto, Candace, Friedman, Joseph H, Lannon, Margaret, Zhang, Lin, Drasby, Edward, Kumar, Rajeev, Subramanian, Thyagarajan, Ford, Donna Stuppy, Grimes, David A, Cote, Diane, Conway, Jennifer, Siderowf, Andrew D, Evatt, Marian Leslie, Sommerfeld, Barbara, Lieberman, Abraham N, Okun, Michael S, Rodriguez, Ramon L, Merritt, Stacy, Swartz, Camille Louise, Martin, WR Wayne, King, Pamela, Stover, Natividad, Guthrie, Stephanie, Watts, Ray L, Ahmed, Anwar, Fernandez, Hubert H, Winters, Adrienna, Mari, Zoltan, Dawson, Ted M, Dunlop, Becky, Feigin, Andrew S, Shannon, Barbara, Nirenberg, Melissa Jill, Ogg, Mattson, Ellias, Samuel A, Thomas, Cathi-Ann, Frei, Karen, Bodis-Wollner, Ivan, Glazman, Sofya, Mayer, Thomas, Hauser, Robert A, Pahwa, Rajesh, Langhammer, April, Ranawaya, Ranjit, Derwent, Lorelei, Sethi, Kapil D, Farrow, Buff, Prakash, Rajan, Litvan, Irene, Robinson, Annette, Sahay, Alok, Gartner, Maureen, Hinson, Vanessa K, Markind, Samuel, and Pelikan, Melisa

Subjects
Parkinson Study Group QE3 Investigators, Humans, Parkinson Disease, Ubiquinone, Antioxidants, Early Diagnosis, Treatment Outcome, Prospective Studies, Double-Blind Method, Dose-Response Relationship, Drug, Aged, Middle Aged, Female, Male, Neurosciences, Brain Disorders, Aging, Neurodegenerative, Prevention, Clinical Research, Parkinson's Disease, Complementary and Integrative Health, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Neurological
Abstract

ImportanceCoenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function, has been shown in preclinical Parkinson disease (PD) models to reduce the loss of dopamine neurons, and was safe and well tolerated in early-phase human studies. A previous phase II study suggested possible clinical benefit.ObjectiveTo examine whether CoQ10 could slow disease progression in early PD.Design, setting, and participantsA phase III randomized, placebo-controlled, double-blind clinical trial at 67 North American sites consisting of participants 30 years of age or older who received a diagnosis of PD within 5 years and who had the following inclusion criteria: the presence of a rest tremor, bradykinesia, and rigidity; a modified Hoehn and Yahr stage of 2.5 or less; and no anticipated need for dopaminergic therapy within 3 months. Exclusion criteria included the use of any PD medication within 60 days, the use of any symptomatic PD medication for more than 90 days, atypical or drug-induced parkinsonism, a Unified Parkinson's Disease Rating Scale (UPDRS) rest tremor score of 3 or greater for any limb, a Mini-Mental State Examination score of 25 or less, a history of stroke, the use of certain supplements, and substantial recent exposure to CoQ10. Of 696 participants screened, 78 were found to be ineligible, and 18 declined participation.InterventionsThe remaining 600 participants were randomly assigned to receive placebo, 1200 mg/d of CoQ10, or 2400 mg/d of CoQ10; all participants received 1200 IU/d of vitamin E.Main outcomes and measuresParticipants were observed for 16 months or until a disability requiring dopaminergic treatment. The prospectively defined primary outcome measure was the change in total UPDRS score (Parts I-III) from baseline to final visit. The study was powered to detect a 3-point difference between an active treatment and placebo.ResultsThe baseline characteristics of the participants were well balanced, the mean age was 62.5 years, 66% of participants were male, and the mean baseline total UPDRS score was 22.7. A total of 267 participants required treatment (94 received placebo, 87 received 1200 mg/d of CoQ10, and 86 received 2400 mg/d of CoQ10), and 65 participants (29 who received placebo, 19 who received 1200 mg/d of CoQ10, and 17 who received 2400 mg/d of CoQ10) withdrew prematurely. Treatments were well tolerated with no safety concerns. The study was terminated after a prespecified futility criterion was reached. At study termination, both active treatment groups showed slight adverse trends relative to placebo. Adjusted mean changes (worsening) in total UPDRS scores from baseline to final visit were 6.9 points (placebo), 7.5 points (1200 mg/d of CoQ10; P = .49 relative to placebo), and 8.0 points (2400 mg/d of CoQ10; P = .21 relative to placebo).Conclusions and relevanceCoenzyme Q10 was safe and well tolerated in this population, but showed no evidence of clinical benefit.Trial registrationclinicaltrials.gov Identifier: NCT00740714.

Published
2014

15. Tourette syndrome deep brain stimulation: A review and updated recommendations

Author

Schrock, Lauren E., Mink, Jonathan W., Woods, Douglas W., Porta, Mauro, Servello, Dominico, Visser-Vandewalle, Veerle, Silburn, Peter A., Foltynie, Thomas, Walker, Harrison C., Shahed-Jimenez, Joohi, Savica, Rodolfo, Klassen, Bryan T., Machado, Andre G., Foote, Kelly D., Zhang, Jian-Guo, Hu, Wei, Ackermans, Linda, Temel, Yasin, Mari, Zoltan, Changizi, Barbara K., Lozano, Andres, Auyeung, M., Kaido, Takanobu, Agid, Yves, Welter, Marie L., Khandhar, Suketu M., Mogilner, Alon Y., Pourfar, Michael H., Walter, Benjamin L., Juncos, Jorge L., Gross, Robert E., Kuhn, Jens, Leckman, James F., Neimat, Joseph A, and Okun, Michael S.

Published
2015
Full Text
View/download PDF

17. Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial

Author

Hass, Chris J., Collins, Mitchell A., and Juncos, Jorge L.

Subjects
Exercise -- Health aspects -- Case studies, Neuromuscular diseases -- Care and treatment -- Case studies -- Health aspects, Homeopathy -- Materia medica and therapeutics, Rehabilitation -- Case studies -- Health aspects, Therapeutics -- Case studies -- Health aspects, Parkinson's disease -- Care and treatment -- Case studies -- Health aspects, Creatine -- Health aspects -- Case studies, Psychology and mental health, Care and treatment, Case studies, Health aspects
Abstract

Background. Persons with Parkinson disease (PD) exhibit decreased muscular fitness including decreased muscle mass, muscle strength, bioenergetic capabilities and increased fatigability. Objective. This purpose of this investigation was to evaluate [...]

Published
2007

21. Reliability of a new scale for essential tremor

Author

Elble, Rodger, Comella, Cynthia, Fahn, Stanley, Hallett, Mark, Jankovic, Joseph, Juncos, Jorge L., LeWitt, Peter, Lyons, Kelly, Ondo, William, Pahwa, Rajesh, Sethi, Kapil, Stover, Natividad, Tarsy, Daniel, Testa, Claudia, Tintner, Ron, Watts, Ray, and Zesiewicz, Theresa

Published
2012
Full Text
View/download PDF

22. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimerʼs diseases

Author

Coppola, Giovanni, Chinnathambi, Subashchandrabose, Lee, Jason JiYong, Dombroski, Beth A., Baker, Matt C., Soto-Ortolaza, Alexandra I., Lee, Suzee E., Klein, Eric, Huang, Alden Y., Sears, Renee, Lane, Jessica R., Karydas, Anna M., Kenet, Robert O., Biernat, Jacek, Wang, Li-San, Cotman, Carl W., DeCarli, Charles S., Levey, Allan I., Ringman, John M., Mendez, Mario F., Chui, Helena C., Le Ber, Isabelle, Brice, Alexis, Lupton, Michelle K., Preza, Elisavet, Lovestone, Simon, Powell, John, Graff-Radford, Neill, Petersen, Ronald C., Boeve, Bradley F., Lippa, Carol F., Bigio, Eileen H., Mackenzie, Ian, Finger, Elizabeth, Kertesz, Andrew, Caselli, Richard J., Gearing, Marla, Juncos, Jorge L., Ghetti, Bernardino, Spina, Salvatore, Bordelon, Yvette M., Tourtellotte, Wallace W., Frosch, Matthew P., Vonsattel, Jean Paul G., Zarow, Chris, Beach, Thomas G., Albin, Roger L., Lieberman, Andrew P., Lee, Virginia M., Trojanowski, John Q., Van Deerlin, Vivianna M., Bird, Thomas D., Galasko, Douglas R., Masliah, Eliezer, White, Charles L., Troncoso, Juan C., Hannequin, Didier, Boxer, Adam L., Geschwind, Michael D., Kumar, Satish, Mandelkow, Eva-Maria, Wszolek, Zbigniew K., Uitti, Ryan J., Dickson, Dennis W., Haines, Jonathan L., Mayeux, Richard, Pericak-Vance, Margaret A., Farrer, Lindsay A., Ross, Owen A., Rademakers, Rosa, Schellenberg, Gerard D., Miller, Bruce L., Mandelkow, Eckhard, and Geschwind, Daniel H.

Published
2012
Full Text
View/download PDF

24. Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?

Author

Shoeibi, Ali, primary, Litvan, Irene, additional, Juncos, Jorge L., additional, Bordelon, Yvette, additional, Riley, David, additional, Standaert, David, additional, Reich, Stephen G., additional, Shprecher, David, additional, Hall, Deborah, additional, Marras, Connie, additional, Kluger, Benzi, additional, Olfati, Nahid, additional, and Jankovic, Joseph, additional

Published
2019
Full Text
View/download PDF

36. Complications of Gamma Knife Surgery for Parkinson Disease

Author

Okun, Michael S., Stover, Natividad P., Subramanian, Thyagarajan, Gearing, Marla, Wainer, Bruce H., Holder, Chad A., Watts, Ray L., Juncos, Jorge L., Freeman, Alan, Evatt, Marian L., Schuele, Stephan U., Vitek, Jerrold L., and DeLong, Mahlon R.

Published
2001

40. Anxiety disorders in patients with Parkinson's disease

Author

Stein, Murray B., Heuser, Isabella J., Juncos, Jorge L., and Uhde, Thomas W.

Subjects
Parkinsonism -- Psychological aspects, Parkinsonism -- Complications, Anxiety -- Causes of, Health, Psychology and mental health
Abstract

Previous research has indicated that individuals with Parkinson's disease are at higher risk for psychiatric disorders. Depression and dementia (impaired cognitive function), in particular, have been associated with victims of Parkinson's disease. Drugs that are typically prescribed for this disorder include compounds that influence brain chemistry and may result in psychiatric symptoms such as delirium and psychosis. Twenty-four patients with Parkinson's disease but no symptoms of dementia participated in this study. Clinical data were obtained and the prevalence of previous psychiatric disorders in these individuals was assessed. Thirty-eight percent (nine individuals) of the patients were diagnosed with an anxiety disorder that was considered clinically significant. This was greater than the five to 15 percent incidence of anxiety disorders estimated in the general population. Lifetime prevalence of social phobia or panic disorder was also higher in the study group. Three general explanations were suggested to account for these results. Anxiety disorders may be the result of a reaction by the individual to having a chronic debilitating illness; psychiatric symptoms may also be a side effect of the drug treatments given for this disease - L-dopa, in particular, is know to cause increased motor fluctuations; and finally, anxiety disorders may be a direct result of the progression of Parkinson's disease, the causal mechanism of which is currently unknown. Because the results of this trial have raised additional questions concerning Parkinson's disease, more research is recommended. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

44. Increased odds of bladder and bowel symptoms in early Parkinson's disease.

Author

Serra, Monica C., Landry, Alexus, Juncos, Jorge L., Markland, Alayne D., Burgio, Kathryn L., Goode, Patricia S., Johnson, II, Theodore M., and Vaughan, Camille P.

Abstract

Aims: To compare the prevalence of urinary and bowel symptoms in a sample of adults with early Parkinson's disease (PD) and healthy controls (HC). Methods: Data were obtained from the Michael J. Fox Parkinson's Progression Markers Initiative (PPMI). Prevalent bladder (urinary incontinence (UI) and nighttime voiding) and bowel (constipation and fecal incontinence (FI)) symptoms were defined as occurring at least sometimes when queried using the Scale for Outcomes in PD for Autonomic Symptoms. Results: The proportion of men (65% vs 64%) and the mean age (61.0 ± 9.7 vs 60.2 ± 11.2 years) was similar between early PD (n = 423) and HC (n = 195). UI and constipation were more prevalent among early PD versus HC (UI: 26.7% vs 8.2%, constipation: 32.4% vs 11.8%; P's < 0.0001). Prevalent nighttime voiding was high among both groups, but not significantly different (82.5% vs 84.1%, P = 0.62). FI was infrequent in both. The odds of UI and constipation were significantly higher in early PD even after adjustment for age, sex, cognition, and overactive bladder (UI model only), constipation (UI and constipation models only), depression, and anxiety medication usage (UI: OR: 4.39 [95% CI: 2.92, 5.87]; constipation: 3.34 [2.20, 4.42]; P's < 0.0001). Conclusions: While constipation is known to precede PD diagnosis, these data suggest that the occurrence of UI is elevated in early PD compared to a well‐matched HC population. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

48. READER OPINIONS

Author

Mitchell, Todd, Juncos, Jorge L., Delong, Mahlon R., Abamonte, Paul, Neil, Tom, Ahmed, Syed R., Shapiro, Marla, Conner, Ginger, Carl, Bryan, and Schultz, Steven P.

Subjects
General interest, News, opinion and commentary
Abstract

Even traditional families can be ugly A recent letter critical of college admissions guidelines described a fictitious student applicant: I do not come from a traditional family. My mother had [...]

Published
2002

50. Aggregation of actin and cofilin in identical twins with juvenile-onset dystonia

Author

Gearing, Marla, primary, Juncos, Jorge L., additional, Procaccio, Vincent, additional, Gutekunst, Claire-Anne, additional, Marino-Rodriguez, Elaine M., additional, Gyure, Kymberly A., additional, Ono, Shoichiro, additional, Santoianni, Robert, additional, Krawiecki, Nicolas S., additional, Wallace, Douglas C., additional, and Wainer, Bruce H., additional

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results